Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: Role of dna methylation

International Journal of Cancer

Volumn 81, Issue 3, 1999, Pages 443-450

  Xing, Rosie H ^a   Rabbani, Shafaat A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; UROKINASE;

ARTICLE; BREAST CANCER; DNA METHYLATION; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MORTALITY; PRIORITY JOURNAL; TUMOR PROMOTION; TUMOR SUPPRESSOR GENE;

EID: 0032940478     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(19990505)81:3<443::aid-ijc19>3.0.co;2-t     Document Type: Article

References (22)

1. ACHBAROU, A., KAISER, S., TREMBLAY, G., SAINTE-MARIE, L.G., BRODT, P., GOLTZMAN, D. and RABBANI, S.A., Urokinase overproduction results in increased skeletal metastasis by prostate cancer in vivo. Cancer Res., 54, 2372-2377 (1994).
2. AHUJA, N., MOHAN, A.L., LI, Q., STOLKER, J.M., HERMAN, J.G., HAMILTON, S.R., BAYLIN, S.B. and ISSA, J.P., Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res., 57, 3370-3374 (1997).
3. BIRD, A.P., CpG-rich island and the function of DNA methylalion. Nature (Lond), 321, 209-213 (1986).
4. DUFFY, M.J., DUGGAN, C., MAGUIRE, T., MULCAHY, K., ELVIN, P., MCDERMOTT, E., FENNELLY, J.J. and O'HIGGINS, N., Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer. Enzyme, Protein, 49, 85-93 (1996).
5. FEINBERG, A.P. and VOGELSTEIN, B., Hypomethylation distinguishes genes of seom human cancers from their normal counterparts. Nature (Lond,), 301, 89-92 (1983a).
6. FEINBERG, A.P. and VOGELSTEIN, B., Hypomethylation of ras oncogenes in primary human cancers. Biochem. biophys. Res. Comm., 111, 47 (1983b).
7. HENDERSON, B.E., ROSS, R. and BERSTEIN, L., Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res., 48, 246-253 (1988).
8. HERMAN, J.G., GRAFF, J.R., MYÖHÄMEN, S., NELKIN, B.D. and Baylin, S.B., Methylation-specific PCR: a novel PCR array for methylation status of CpG islands. Proc. nAt. Acad. Sci. (Wash.), 93, 9821-9826 (1996).
9. HERMAN, J.G., LATIF, F., WENG, Y., LERMAN, M.I., ZBAR, B., LIU, S., SAMID, D., DUAN, D.S., GNARRA, J.R., LINEHAN, W.M. and BAYLIN, S.B., Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. natl. Acad. Sci.( Wash.), 91, 9700-9704 (1994).
10. JÄNICKE, F., SCHMITT, M, and GRAEFF, H., Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin. Thrombosis Hemostasis, 17, 303-312 (1991).
11. MACLEOD, A.R., ROULEAU, J. and SZYF, M., Regulation of DNA methylation by the ras signaling pathway. J. biol. Chem., 270, 11327-11337 (1995).
12. MERLO, A., HERMAN, J.G., MAO, L., LEE, D.J., GABRIELSON, E., BURGER, P., BAYLIN, S.B. and SIDRANSKY, D., 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancer. Nature (Med.), 1, 686-692 (1995).
13. OHTANI-FUJITA, N., FUJITA, T., AOIKE, A., OSIFCHIN, B.E., ROBBINS, P.D. and SAKAI, T., CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogens, 8, 1063-1067 (1993).
14. OTTAVIANO, Y.L., ISSA, J-P. J., PARL, F.F., SMITH, H.S., BAYLIN, S.B. and DAVIDSON, N.E., Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res., 54, 2552-2555 (1994).
15. RICCIO, A., GRIMALDI, G., VERDE, P., SEBASTIO, G., BOAST, S. and BLASI, F. The human urokinase-plasminogen activator gene and its promoter. Nucleic Acid Res., 13, 2759-2771 (1985).
16. ROGHANI, M., MOHAMMADI, M., SCHLESSINGER, J. and MOSCATELLI, D., Induction of urokinase-type plasminogen activator by fibroblast growth factor (FGF)-2 is dependent on expression of FGF receptors and does not require activation of phospholipase Cgamma 1. J. biol. Chem., 271, 31154-31159 (1996).
17. SZYF, M., DNA methylation properties: consequences for pharmacology. Trends Pharmacol. Sci., 7, 233-238 (1994).
18. tOLLERVEY, D., Trans-activating factors in ribosome synthesis. Exp. Cell Res., 229, 226-232 (1996).
19. VASSALI, J.D. and PEPPER, M.S., Membrane proteases in focus. Nature (Lond.), 319, 14-15 (1994).
20. XING, R.H., MAZAR, A., HENKIN, J. and RABBANI, S.A., Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res., 57, 3585-3593 (1997).
21. XING, R.H. and RABBANI, S.A., Overexpression of urokinase receptor in breast cancer results in increased tumor invasion, growth and metastasis. Int. J. Cancer, 67, 423-429 (1996).
22. YOSHIURA, K., KANAI, Y., OCHIAI, A., SHIMOYAMA, Y., SUGIMURA, T. and HIROHASHI, S., Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc. nat. Acad. Sci. (Wash.), 92, 7416-7419 (1995).